SCHEMBL907673

SCHEMBL907673

CCC1CC(N)=NN1c1cccc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PRKCZ Q05513 1/20 0.43
▸ BPTF Q12830 1/20 0.38
▸ GRM2 Q14416 1/20 0.37
▸ NOTUM Q6P988 1/20 0.36
▸ KDM1A O60341 1/20 0.36
▸ RCOR1 Q9UKL0 1/20 0.36
▸ PI4KA P42356 1/20 0.35
▸ PI4K2B Q8TCG2 1/20 0.35
▸ PI4K2A Q9BTU6 1/20 0.35
▸ PI4KB Q9UBF8 1/20 0.35
▸ KEAP1 Q14145 1/20 0.34
▸ ALOX5 P09917 1/20 0.34
▸ C1S P09871 1/20 0.34
▸ RXRA P19793 1/20 0.34
▸ GRIN1 Q05586 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11191975 0.83 ALOX5 (0.50) PRKCZNOTUMKDM1ARCOR1ALOX5
SCHEMBL7719325 0.82 ALDH1A1 (0.39) PRKCZKDM1ARCOR1MEN1KMT2A
SCHEMBL7717975 0.82 ALDH1A1 (0.39) PRKCZMEN1KMT2AL3MBTL1
SCHEMBL907869 0.81 PRKCZ (0.45) PRKCZBPTFNOTUMPI4KAPI4K2B
SCHEMBL7719894 0.76 ABL1 (0.46) NOTUML3MBTL1
SCHEMBL11095289 0.76 PRKCZ (0.52) PRKCZMEN1KMT2AL3MBTL1
SCHEMBL908495 0.74 HSD17B10 (0.39) GRM2NOTUMKDM1ARCOR1MEN1
SCHEMBL7719098 0.74 PRKCZ (0.39) PRKCZ
SCHEMBL11068397 0.73 PRKCZ (0.52) PRKCZ
SCHEMBL7714597 0.71 DPP4 (0.37) PRKCZGRM2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases MERCK SHARP & DOHME LIMITED (GB) 2011-01-06 — — US claimed
EP-1987007-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LTD. (GB) 2008-11-05 — — EP claimed
WO-2007093829-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LIMITED (GB) 2007-08-23 — — WO claimed
US-4451479-A ANTIINFLAMMATORY AMERICAN CYANAMID COMPANY (US) 1984-05-29 — — US claimed
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases MERCK SHARP & DOHME LIMITED (GB) 2011-01-06 — — US disclosed
EP-1987007-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LTD. (GB) 2008-11-05 — — EP disclosed
WO-2007093829-A1 3-AMINOPYRAZOLINES FOR TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES MERCK SHARP & DOHME LIMITED (GB) 2007-08-23 — — WO disclosed
US-4451479-A ANTIINFLAMMATORY AMERICAN CYANAMID COMPANY (US) 1984-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003862-A1 3-Animopyraolines for Treatment of Neurodegenerative and Psychiatric Diseases DAO, DDO, MAOA PRKCZ 2127/4885BPTF 4033/4885GRM2 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback